Tafamidis treats transthyretin amyloid cardiomyopathy

September 18, 2018

(HealthDay)—In patients with transthyretin amyloid cardiomyopathy, treatment with tafamidis reduces all-cause mortality and cardiovascular-related hospitalizations versus placebo, according to a study published in the Sept. 13 issue of the New England Journal of Medicine.

Mathew S. Maurer, M.D., from Columbia University in New York City, and colleagues randomly assigned 441 patients with transthyretin amyloid cardiomyopathy in a 2:1:2 ratio to receive tafamidis 80 mg, tafamidis 20 mg, or placebo for 30 months.

The researchers found that all-cause mortality (hazard ratio, 0.7) and rates of cardiovascular-related hospitalizations (relative risk ratio, 0.68) were lower among the 264 patients who received tafamidis than the 177 patients who received placebo. Tafamidis was also associated with a lower rate of decline in distance for the six-minute walk test and a lower rate of decline in Kansas City Cardiomyopathy Questionnaire-Overall Summary score at month 30. Incidence and types of adverse events were similar between the two groups.

"In with transthyretin amyloid , tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the in functional capacity and quality of life as compared with ," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which funded the study.

Explore further: Drug reduces deaths and hospitalizations from underdiagnosed form of heart failure

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Drug reduces deaths and hospitalizations from underdiagnosed form of heart failure

August 27, 2018
A phase three clinical trial has shown that a drug called tafamidis significantly reduces deaths and hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive form of heart failure that ...

Researchers discover first treatment to improve survival in rare heart condition

August 27, 2018
Tafamidis is the first treatment to improve survival and reduce hospitalisations in a rare heart condition called transthyretin amyloid cardiomyopathy, according to late breaking research presented today in a Hot Line Session ...

Patisiran, inotersen aid hereditary transthyretin amyloidosis

July 6, 2018
(HealthDay)—For patients with hereditary transthyretin amyloidosis with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2'-O-methoxyethyl-modified antisense oligonucleotide (inotersen), ...

Escitalopram cuts MACE risk in depressed patients with ACS

July 25, 2018
(HealthDay)—For patients with depression following recent acute coronary syndrome (ACS), escitalopram results in lower risk of major adverse cardiac events (MACE) versus placebo, according to a study published in the July ...

Worse health status with shorter telomere length in COPD

September 13, 2018
(HealthDay)—Patients with chronic obstructive pulmonary disease (COPD) with shorter telomere length have worse health status, according to a study published in the August issue of CHEST.

Tafamidis: Approval denotes proven added benefit

September 17, 2012
Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with ...

Recommended for you

Can stem cells help a diseased heart heal itself? Researchers achieve important milestone

December 14, 2018
A team of Rutgers scientists, including Leonard Lee and Shaohua Li, have taken an important step toward the goal of making diseased hearts heal themselves—a new model that would reduce the need for bypass surgery, heart ...

Higher risk of heart attack on Christmas Eve

December 12, 2018
The risk of heart attack peaks at around 10pm on Christmas Eve, particularly for older and sicker people, most likely due to heightened emotional stress, finds a Swedish study in this week's Christmas issue of The BMJ.

Your weight history may predict your heart failure risk

December 12, 2018
In a medical records analysis of information gathered on more than 6,000 people, Johns Hopkins Medicine researchers conclude that simply asking older adult patients about their weight history at ages 20 and 40 could provide ...

Age is the biggest risk for heart disease, but lifestyle and meds have impact

December 12, 2018
Of all the risk factors for heart disease, age is the strongest predictor of potential trouble.

New understanding of mysterious 'hereditary swelling'

December 12, 2018
For the first time ever, biomedical researchers from Aarhus University, Denmark, report cellular defects that lead to a rare disease, hereditary angioedema (HAE), in which patients experience recurrent episodes of swelling ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.